## Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. and Teva Canada Limited that the shortages for TaroBudesonide $0.125 \mathrm{mg} / \mathrm{ml}$ Inhalation Suspension (DIN 02494264 ) and Teva- Budesonide $0.125 \mathrm{mg} / \mathrm{ml}$ Inhalation Suspension (DIN 02465949), respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective April 6, 2022. The following grouping was removed from the Critical Supply Product List on March 7, 2022.

BUDESONIDE

### 0.125 MG / ML INHALATION SUSPENSION

| $\mathbf{0 0 0 0 2 4 9 4 2 6 4}$ | TARO-BUDESONIDE 0.125 MG / ML INH SUS | TAR | $\mathbf{\$ 0 . 1 1 4 3}$ |
| :--- | :--- | :--- | :--- |
| $\mathbf{0 0 0 0 2 4 6 5 9 4 9}$ | TEVA-BUDESONIDE 0.125 MG / ML INH SUS | TEV | $\mathbf{\$ 0 . 1 1 4 3}$ |
| 00002229099 | PULMICORT NEBUAMP | AZC | $\$ 0.2375$ |

Alberta Blue Cross has been advised by Apotex Inc. and Jamp Pharma Corporation that the shortages for Apo-Darifenacin 7.5 mg Extended-Release Tablet (DIN 02452510) and Jamp Darifenacin 7.5 mg Extended-Release Tablet (DIN 02491869), respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective May 12, 2022. The following grouping was removed from the Critical Supply Product List on April 12, 2022.

## DARIFENACIN HYDROBROMIDE

7.5 MG EXTENDED-RELEASE TABLET

| $\mathbf{0 0 0 0 2 4 5 2 5 1 0}$ | APO-DARIFENACIN 0.125 MG/ML INH SUS | APX | $\mathbf{\$ 0 . 8 0 5 8}$ |
| :--- | :--- | :--- | :--- |
| $\mathbf{0 0 0 0 2 4 9 1 8 6 9}$ | JAMP DARIFENACIN 0.125 MG/ML INH SUS | JPC | $\mathbf{\$ 0 . 8 0 5 8}$ |
| 00002273217 | ENABLEX | SLP | $\mathbf{\$ 1 . 6 4 0 0}$ |

# Removal of temporary benefit from the Alberta Drug Benefit List (ADBL) 

Due to the shortage for Nestle Materna Tablet (DIN 80082297) manufactured by Nestle Canada Inc., Prenatal 100\% Complete Multivitamin Tablet (DIN 80075639) manufactured by Jamieson Laboratories Ltd. was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Nestle Canada Inc. has advised Alberta Blue Cross that the shortage for Nestle Materna Tablet (DIN 80082297) has been resolved.
As a result, Prenatal 100\% Complete Multivitamin Tablet (DIN 80075639) will no longer be considered a temporary benefit for the ADBL after April 15, 2022. The following grouping was removed from the Critical Supply Product List on March 17, 2022.

## DARIFENACIN HYDROBROMIDE

| 7.5 MG EXTENDED-RELEASE TABLET |  |  |  |
| :--- | :--- | :--- | :--- | :--- |
| $\mathbf{0 0 0 0 2 4 5 2 5 1 0}$ | APO-DARIFENACIN 0.125 MG/ML INH SUS | APX | $\mathbf{\$ 0 . 8 0 5 8}$ |
| $\mathbf{0 0 0 0 2 4 9 1 8 6 9}$ | JAMP DARIFENACIN 0.125 MG/ML INH SUS | JPC | $\mathbf{\$ 0 . 8 0 5 8}$ |
| 00002273217 | ENABLEX | SLP | $\$ 1.6400$ |

## Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Trurapi 100 unit/ml Injection Cartridge (DIN 02506564) and Trurapi Solostar 100 unit/ ml Pen Injection (DIN 02506572) manufactured by Sanofi - Aventis, Novorapid Flextouch 100 unit/ml Injection (DIN 02377209) will be considered as a temporary benefit for the Alberta Drug Benefit List (ADBL). The following grouping was added to the Critical Supply Product List April 28, 2022.

As of April 20, 2022, all claims Novorapid Flextouch 100 unit/ml Injection (DIN 02377209) will be adjudicated to the price published in the most recent Alberta Blue Cross Drug Price List (ABCDPL) until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free) Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

## ALBERTA

BLUE CROSS ${ }^{\circ}$

